Live Attenuated Polio Vaccine Market Report 2026

Live Attenuated Polio Vaccine Market Overview

• Live Attenuated Polio Vaccine market size has reached to $1.98 billion in 2025 • Expected to grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Expansion Of Immunization Programs Fueling The Growth Of The Market Due To Enhanced Vaccine Accessibility And Disease Prevention • Market Trend: Regulatory Approvals For Next-Generation Live Attenuated Polio Vaccines • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Live Attenuated Polio Vaccine Market?

The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) that contains a weakened form of the poliovirus that stimulates a strong immune response without causing disease in healthy individuals. It mimics natural infection, offering long-lasting immunity and helping prevent virus transmission within communities. The main types of vaccines in live attenuated polio vaccine are monovalent, bivalent, and trivalent. A monovalent oral polio vaccine (mOPV) is designed to protect against only one specific type of poliovirus, either type 1, type 2, or type 3. It is administered through oral administration, intramuscular injection, or subcutaneous injection for various age groups, including infants (0-1 years), children (1-5 years), and adults (above 5 years). It caters to various end users, including hospitals, clinics, public health agencies, and other end users.

What Is The Live Attenuated Polio Vaccine Market Growth Forecast?

The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to continued eradication efforts in remaining endemic regions, rising focus on outbreak prevention, expansion of vaccination coverage in underserved populations, increased funding for public health immunization programs, growing emphasis on vaccine accessibility and affordability. Major trends in the forecast period include continued use of oral polio vaccines in mass immunization, strong focus on community-level immunity and transmission control, sustained demand in polio-endemic and high-risk regions, integration of lapv in national immunization programs, emphasis on long-lasting immunity in pediatric vaccination.

Global Live Attenuated Polio Vaccine Market Segmentation

1) By Vaccine Type: Monovalent, Bivalent, Trivalent 2) By Age Group: Infants (0-1 years), Children (1-5 years) 3) By End-User: Clinics, Public Health Agencies, Other End-Users Subsegments: 1) By Monovalent: mOPV1 For Serotype 1 2) By Bivalent: Type 1, Type 3 3) By Trivalent: Poliovirus Type 1, Poliovirus Type 2, Poliovirus Type 3

What Is The Driver Of The Live Attenuated Polio Vaccine Market?

The expansion of immunization programs is expected to propel the growth of the live attenuated polio vaccine market going forward. Immunization programs refer to organized efforts by governments, health organizations, or other institutions to provide vaccines to populations to prevent the spread of infectious diseases. The expansion of immunization programs is primarily due to increased global awareness of the importance of disease prevention and strong support from governments, international health organizations, and funding bodies. Immunization programs support the live attenuated polio vaccine (LAPV) by ensuring widespread distribution, safe administration, and high coverage to build herd immunity, prevent virus transmission, and aid in global polio eradication. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government agency, during the 2023–2024 season, a school-based programme targeting all children aged 4 to 16 years (Reception to Year 11) in England saw 52.2% of eligible children in Reception to Year 9 (3,498,576 out of 6,708,016) receive the vaccine. This is slightly higher than the 51.9% coverage (3,502,566 out of 6,747,523) recorded in the 2022–2023 season. Therefore, the expansion of immunization programs is driving the growth of the live attenuated polio vaccine industry.

Key Players In The Global Live Attenuated Polio Vaccine Market

Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Biological E Limited, Indian Immunologicals Limited, Bharat Biotech International Limited, Panacea Biotec, Haffkine Biopharmaceutical, Bio Farma, Bilthoven Bio, Vabiotech, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., LG Chem Ltd., Chumakov Federal Scientific Center, Institute of Poliomyelitis and Viral Encephalitides, Statens Serum Institut, Federal State Unitary Enterprise Microgen, Pasteur Institute of Iran, Institut Pasteur de Dakar

Global Live Attenuated Polio Vaccine Market Trends and Insights

Major companies operating in the live attenuated polio vaccine market are focusing on obtaining regulatory approvals to ensure their vaccines meet the safety and efficacy standards required by health authorities globally. Regulatory approvals refer to the formal authorization granted by government health agencies or regulatory bodies, allowing a product, such as a vaccine, to be marketed, sold, and used within a specific region or country. For instance, in July 2024, Biological E, an India-based pharmaceutical and biologics company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2), a next-generation live, attenuated oral vaccine designed to address the challenges associated with traditional oral polio vaccines. This next-generation vaccine is designed to combat circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks more effectively than its predecessor. nOPV2 is engineered with enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form, which has been a concern with older vaccines.

What Are Latest Mergers And Acquisitions In The Live Attenuated Polio Vaccine Market?

In June 2024, SK bioscience, a South Korea-based vaccine and biotech company, acquired IDT Biologika for approximately $244 million. With this acquisition, SK bioscience aims to strengthen its vaccine development and manufacturing leadership, expanding its capabilities and service offerings to drive global health improvements and align with its vision for operational growth and innovation. IDT Biologika is a Germany-based contract development and manufacturing organization for viral vaccines, including live attenuated virus vaccines.

Regional Outlook

North America was the largest region in the live attenuated polio vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Live Attenuated Polio Vaccine Market?

The live attenuated polio vaccine market consists of sales of monovalent oral polio vaccine (mOPV), bivalent oral polio vaccine (bOPV), novel oral polio vaccine, and trivalent oral polio vaccine (tOPV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Live Attenuated Polio Vaccine Market Report 2026?

The live attenuated polio vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated polio vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.